



Teva Innovative Medicine Pipeline



Teva Biosimilar Franchise



Pipeline is current as of July 31, 2024

1. In collaboration with Alvotect for the U.S. Market
2. In collaboration with mAbxience
3. In collaboration with Celltrion in the U.S. and Canada
4. In collaboration with BioEq in the UK (marketed as ONGAVIA®), in the EU (marketed as RANIVISIO®) and in Canada (marketed as RANOPTO™)